Oral Microbiome Therapy for Recurrent C. Diff Mostly Holds Up at 6 Months

(MedPage Today) -- WASHINGTON--Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.
Of the 182 patients in the...